Padnarsertib is under clinical development by Karyopharm Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Padnarsertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Padnarsertib overview
KPT-9274 is under development for the treatment of advanced solid malignancies including non-small cell lung cancer, relapsed or refractory acute myeloid leukemia, acute myeloid leukemia and non-Hodgkin's lymphoma. The drug candidate is administered through the oral route. It acts by targeting PAK4 and NAMPT.
It was under development for the treatment of colorectal cancer, triple negative breast cancer, renal cell carcinoma, acute myeloid leukemia, Waldenstrom macroglobulinemia, pancreatic ductal adenocarcinoma, non-small cell lung cancer, melanoma, colon cancer, resistant pancreatic neuroendocrine tumors, sarcomas and Non-Hodgkin Lymphoma.
Karyopharm Therapeutics overview
Karyopharm Therapeutics (Karyopharm Therapeutic) discovers and develops novel drugs for the treatment of cancer and other diseases. The company’s core technology harnesses the inhibition of nuclear export as a mechanism to treat patients suffering from cancer. Karyopharm’s lead product, Xpovio, is recommended for the treatment of multiple myeloma, and relapsed or refractory diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, eltanexor, verdinexor, and KPT-9274. Karyopharm’s drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and endometrial cancer. The company has operations in the US, Israel, and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.
For a complete picture of Padnarsertib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
